News & Trends - Pharmaceuticals
Vaccine hub to deliver personalised cancer therapies: $7 billion opportunity over the next decade

Pharma News: A new facility is set to provide Australian researchers with personalised cancer vaccines. Backed by a $3.3 million grant from the Medical Research Future Fund’s (MRFF), the lab at The University of Queensland’s Australian Institute for Bioengineering and Nanotechnology (AIBN) will bring together the equipment and expertise to enable the design, manufacture and delivery of new mRNA cancer vaccines.
Dr Seth Cheetham, Deputy Director of AIBN’s BASE facility, said it could transform cancer treatment.
“Personalised mRNA cancer vaccines are now being used to train the body’s immune system to recognise and eradicate cancer cells,” Dr Cheetham said. “Despite the huge potential, Australian researchers haven’t had the necessary infrastructure to build these vaccines, leading to a critical gap in the local drug development pipeline.”
“This lab changes that, with a leading team of investigators in a purpose-built space, working with local industry and academics to progress a range of high-quality mRNA cancer vaccine candidates from design through to preclinical evaluation, with the aim of enabling future clinical trials,” he added.
Mark Butler MP, Federal Minister for Health and Aged Care, said “Cancer affects so many families, and mRNA vaccines are a promising new approach. This funding will create the infrastructure to produce and research mRNA cancer vaccines right here in Australia.”
The mRNA cancer vaccine hub is expected to be operating in BASE by late 2024. BASE is already recognised as Australia’s leading provider of mRNA for research and pilot studies, and since its launch in 2021 has provided academic and industry partners with more than 300 experimental grade vaccines.
“As well as the potential impacts on patient health, mRNA cancer vaccines represent a $7 billion opportunity over the next decade,” Dr Cheetham said.
“This is a rapidly expanding industry encompassing researchers, biotech start-ups and multinational pharmaceuticals, and AIBN and BASE will now be at the centre of a range of promising new treatment options.”
The new lab was one of four UQ projects funded in the latest MRFF grant round, adding to the $6.6 million funding awarded to BASE in 2023 to boost clinical mRNA production capabilities.
AIBN Director, Professor Alan Rowan, said the hub would complement Australia’s existing research strengths in oncology and affirm AIBN as a therapeutics and personalised medicine pipeline.
“Governments and society want sustainable innovation that enables high quality research and delivers translatable outcomes,” Professor Rowan said. “The mRNA cancer vaccine hub is the latest example of how AIBN combines world class infrastructure and technical expertise to bridge the gap between research and clinical development.”
The 5-year program will also bring together partner investigators from UQ, QIMR-Berghofer, Mater Research, Garvan Institute of Medical Research and the Queensland Children’s Hospital.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - MedTech & Diagnostics

Government’s claim of progress in genomics falls flat while it fails to uphold the fundamental rights of Aussies
The government has unveiled Cancer Australia’s National Framework for Genomics in Cancer Control, a strategic plan designed to guide healthcare […]
MoreNews & Trends - Pharmaceuticals

Healthcare sector’s political donations: What to expect ahead of the federal election
Ahead of the upcoming federal election, attention turns to the financial contributions to major political parties. The Australian Electoral Commission’s […]
MoreNews & Trends - Pharmaceuticals

‘Underinvestment in gynae cancer has left critical gaps,’ says ANZGOG Chair
Ovarian cancer is the deadliest women’s cancer, with the latest statistics revealing a five-year survival rate of just 49%. Alarmingly, […]
MoreNews & Trends - MedTech & Diagnostics

Labor’s one-off funding a band aid for public hospitals while private sector left in limbo
The Federal Government has committed a one-off funding boost of $1.7 billion to public hospitals under a one-year extension to […]
More